In a notable revision that has caught the attention of investors, Soleno Therapeutics, Inc. (NASDAQ: SLNO) received a Neutral rating from Kristen Kluska of Cantor Fitzgerald on April 6, 2026. This shift in sentiment comes despite the stock currently priced at $52.25, presenting a price target of $53, suggesting limited upside potential in the near term. Investors are keenly analyzing how these developments may impact the company’s standing in a fluctuating market.
Recent Price Action
SLNO has experienced significant volatility in its stock price, which has become a focal point for traders and investors alike. After rising sharply by 12.76% in its latest session, the stock is currently valued at $52.25. Despite this recent uptick, the price trajectory over the year has been tumultuous, recording a 52-week high of $57.83 and a low of $3.87. This wide price range underscores a substantial level of volatility, indicative of the challenges the company has faced. Trading volume has also surged, with 58,033,832 shares exchanging hands, significantly higher than its average volume of 1,689,125. The market capitalization stands at approximately $2.81 billion, while the stock exhibits a high beta of -2.805, highlighting its inverse relationship to broader market movements.
[chart type=’price’ value=’SLNO’]
Short- and Long-Term Performance
Examining Soleno’s performance over multiple time frames presents a mixed picture. Over the past 30 days, the stock has declined by 11.21%, reflecting investor apprehension amid broader sector pressures. The quarterly performance has been even steeper, down 33.21%, signaling multiple headwinds the company has faced. Over a longer horizon, the stock is down 4.91% year-to-date. With weekly volatility measured at 5.28% and monthly volatility at 5.69%, the stock’s performance remains unpredictable, demanding careful monitoring from potential investors.
[chart type=’performance’ value=’SLNO’]
Earnings and Financials
In its most recent earnings report dated November 4, 2025, SLNO reported earnings per share (EPS) of $0.47, significantly surpassing the estimate of $0.0575 with a surprise factor of an impressive 717.39%. This remarkable performance starkly contrasts with the previous quarter, where the EPS was -$0.09, falling short of the estimate of -$0.53 and marking an 83.02% surprise downside. The dramatic shifts in EPS highlight the unpredictable nature of the company’s earnings stability and suggest a potentially volatile trajectory moving forward.
[chart type=’income-bar-chart’ value=’SLNO’]
Analyst Consensus View
The consensus outlook for SLNO reflects a cautious optimism tempered with clear reservations. According to the latest ratings, there are currently seven analysts covering the stock, with six recommending it as a Buy and one advising a Hold, yet no Sell ratings have been noted. The average price target stands at $103, with expectations ranging widely from a low of $53 to a high of $120. While the investment community remains bullish overall, Kluska’s shift to a Neutral rating suggests a reevaluation amidst market uncertainties, hinting that upside may not be as robust as previously anticipated.
[chart type=’analyst-ratings’ value=’SLNO’]
Stock Grading or Fundamental View
The Stocks Telegraph Grading Score for Soleno Therapeutics, Inc. is currently at 53, suggesting a mixed assessment of the company’s overall investment profile based on financial health and market performance analysis. This score indicates that while the company may have favorable aspects, it does not exhibit the strong fundamentals or leadership in innovation that would signal a robust investment opportunity.
[chart type=’st-cards’ value=’SLNO’]
Conclusion
In summary, Soleno Therapeutics, Inc. (SLNO) represents a complex case for investors. The stock’s recent rise amid analyst downgrades, coupled with an impressive earnings surprise, highlights both potential and risk. While momentum-driven investors may find it intriguing given its current pricing and volatility, those looking for stability or long-term growth may need to exercise caution. A diversified investment approach, encompassing the inherent risks of high volatility and market sentiment, may be a prudent strategy for those considering entry into SLNO.